JTA-004, is a patented, non-cellular viscosupplement product for the treatment of knee osteoarthritis (KOA), which Bone Therapeutics has been developing in parallel with its core cell therapy pipeline and addressing its mission of bringing innovative solutions to orthopaedic conditions.
Viscosupplements are injectable solutions containing hyaluronic acid (HA), a main component of knee joint’s synovial fluid and aim to provide added lubrication and protection to the cartilage of the arthritic joint.
JTA-004, which consists of hyaluronic acid, an analgesic and anti-inflammatory agent and an enriched protein solution, showed distinct advantages other viscosupplements due to its analgesic and lubrication properties.
Warning: JTA-004 is an investigational product and is not yet available for sale. This website is not intended to provide medical advice or as a substitute for professional healthcare. Consult your doctor or medical provider for information about your diagnosis, treatment or condition.